

Serial No.: 09/244,130

96. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*CsmI* site.
97. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*PanI* site.
98. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*SceII* site.
99. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*CeuI* site.
100. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*PpoI* site.
101. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*SceIII* site.
102. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*CreI* site.
103. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*TevI* site.
104. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*TevII* site.
105. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*TevIII* site.
106. (NEW) The transgenic mouse of claim 94, wherein the site is an I-*SceI* site.
107. (NEW) A method of culturing transgenic cells comprising the steps of:
- (a) providing a cell from a transgenic mouse in which at least one Group I intron encoded endonuclease recognition site is inserted at a unique location in a chromosome of said cell,

wherein the site is selected from the group consisting of an I-*SceIV* site, an I-*CsmI* site, I-*PanI* site, I-*SceII* site, an I-*CeuI* site, an I-*PpoI* site, an I-*SceIII* site, an I-*CreI* site, an I-*TevI* site, an I-*TevII* site, an I-*TevIII* site, and an I-*SceI* site; and
 - (b) culturing said cell under conditions that allow growth of said cell.
108. (NEW) The method of claim 107, wherein the site is an I-*SceIV* site.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com